Notable Volumers: Calithera Biosciences (CALA), Life Time Fitness (LTM), Celladon (CLDN), Geron Corp (GERN)

Calithera Biosciences, Inc. (CALA) today is printing a much higher than average trading volume with the issue trading 1.24 million shares, compared to the average volume of 198.45K. The stock began trading this morning at $17.99 to currently trade 14.20% higher from the prior days close of $13.31. On an intraday basis it gotten as low as $14.87 and as high as $18.00. Calithera Biosciences announced yesterday an exclusive global license agreement with TransTech Pharmaob to develop and commercialize a portfolio of preclinical compounds aimed at treating cancer.

The South San Francisco, Cali.-based company, which is currently valued at $272 million, has a median Wall Street price target of $25.00 with a high target of $30.00. CALA is up 61.42% year-over-year ; down 24.80% year-to-date.

Life Time Fitness, Inc. (LTM) gained more than 15% in midday trading today. About 2.1 million shares of Chanhassen, Minnesota-based gym operator were traded as of 1:30 p.m. est, compared to the normal trading volume of 255K shares a day. Life Time Fitness is in advanced talks with private equity bidders to sell itself, the Wall Street Journal reported. KSL Capital Partners LLC and another unnamed private equity firm are bidding on the chain of fitness centers, according to sources cited by the publication. Bidding is expected to come to a close next week.

Shares of LTM are currently trading up $8.72 to $66.39.

Celladon Corporation (CLDN) is trading at unusually high volume Friday with 2.28 million shares changing hands. It is currently at 7x its average daily volume and trading up 15.61% at $24.76. Barron’s suggests the developer of gene therapy for heart failure may have upside to $70 a share, implying 182.50% expected return.

Geron Corporation (GERN) shares are down 6.35% in midday trading. The move comes on a big volume too with the issue currently trading more than 10.8 million shares, well above the average of 3.15 million for a full session over the past month. In a new article, Barron’s notes GERN shares could reach $6 in one year.

In the past 52 weeks, shares of Menlo Park, California-based clinical stage biopharmaceutical company have traded between a low of $1.31 and a high of $4.41 and are now at $3.50. Shares are down 16.19% year-over-year ; up 16.31% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*